Clinical Trials Directory

Trials / Completed

CompletedNCT02460432

Comparison of Drug Eluting Stent and Covered Metal Stent in Malignant Biliary Obstruction (MIRA III)

A Prospective, Randomized, Single Blind Study to Evaluate the Effectiveness and Safety Comparing Niti-S Mira-Cover III Biliary Stent With ComVi Biliary Covered Stent in Patients With Malignant Biliary Obstruction

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
106 (actual)
Sponsor
Taewoong Medical Co., Ltd. · Industry
Sex
All
Age
19 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to compare the effectiveness and safety of Niti-S Mira-Cover III Biliary Stent with Comvi Biliary Covered Stent for the treatment of malignant biliary obstruction.

Detailed description

In patients with malignant biliary obstruction, endoscopic placement of biliary stents offers similar technical success rates. Endoscopic retrograde cholangiography (ERCP)-guided stent placement has become the preferred approach to palliate malignant biliary obstruction. The major mechanisms of self-expandable metallic stent (SEMS) occlusion are tumor ingrowth, tumor overgrowth, and epithelial hyperplasia. These mechanisms provide the rationale for developing a drug-eluting stent in order to improve stent patency. Limited data exist regarding outcomes of paclitaxel-eluting stents in malignant biliary obstruction. This study is to prospectively compare the effectiveness and safety of paclitaxel-eluting covered metal stent and covered metal stent for the treatment of malignant biliary obstruction.

Conditions

Interventions

TypeNameDescription
DEVICEPaclitaxel-eluting metal StentInsertion of Niti-S Mira-Cover III Biliary Stent using ERCP
DEVICECovered Metal StentInsertion of ComVi Biliary Covered Stent using ERCP

Timeline

Start date
2015-05-01
Primary completion
2016-12-26
Completion
2016-12-26
First posted
2015-06-02
Last updated
2017-04-11

Locations

5 sites across 1 country: South Korea

Source: ClinicalTrials.gov record NCT02460432. Inclusion in this directory is not an endorsement.